NEW YORK, Dec. 17, 2013 /PRNewswire/ -- Nearly 900 Biomet hip lawsuits (http://www.consumerinjurylawyers.com/biomet-magnum-hip-replacement) filed on behalf of plaintiffs who were allegedly injured by the Biomet M2a Magnum hip continue to move forward in a multidistrict litigation underway in U.S. District Court, Northern District of Indiana, Bernstein Liebhard LLP reports. According to court documents, the next Case Management Conference in the Biomet hip replacement litigation has been scheduled for January 6, 2014. (In re: Biomet M2a Magnum Hip Implant Products Liability Litigation – MDL No. 2391)
"We are looking forward to additional progress in this litigation in the coming year, as we are representing a number of Biomet hip lawsuit clients in this proceeding," says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The Firm continues to offer free and confidential legal consultations to individuals who may have been injured by this metal-on-metal Biomet hip replacement system.
Biomet Hip Replacement Lawsuits
Court documents indicate that nearly 900 Biomet hip lawsuits have been filed in the Northern District of Indiana since the multidistrict litigation was established in October 2012. The lawsuits pending in the proceeding involve the Biomet M2a Magnum Hip Replacement System, a metal-on-metal hip that consists of a chromium/cobalt femoral ball and acetabular cup. Plaintiffs in Biomet hip replacement claims allege that this design places recipients at risk for serious complications, including metallosis, pseudotumor formation, and early failure of the device, due to the accumulation of toxic metal ions that are shed from the hip when the components rub together. According to these lawsuits, many M2a Magnum hip recipients have had to undergo painful revision surgery because of these types of complications.
Metal-on-metal hip implants, like the Biomet M2a Magnum, have been the subject of a U.S. Food & Drug Administration (FDA) safety review since 2011. In January 2013, the agency issued a proposed order requiring manufacturers of metal-on-metal total hips to submit premarket approval (PMA) applications. The proposal would make such devices ineligible for 510(k) clearances, which do not require that a device undergo human testing if it can be shown it is substantially equivalent to a product previously approved by the FDA. The proposed regulation would also require manufacturers of all-metal hips already on the market to conduct safety studies of their devices in order to continue selling them.
In January 2013, the FDA also issued a safety communication in which it warned that metal debris released by an all-metal hip may result in damage to bone and/or soft tissue surrounding the implant and joint. Some of the metal ions released will enter the bloodstream and travel to other parts of the body, where they may cause symptoms or illnesses elsewhere in the body, the agency said. The FDA has recommended that metal-on-metal hip implant recipients who develop any symptoms or physical findings that indicate their device may not be functioning properly should be considered for metal ion testing.
Biomet M2a Magnum hip recipients who suffered metallosis, pseudotumor formation, or early device failure may be eligible to file their own Biomet hip lawsuit to obtain compensation for any injury-related damages they sustained. To learn more about the litigation surrounding the Biomet hip replacement and other metal-on-metal hip implants, please visit Bernstein Liebhard LLP's website. To arrange for a free case review, please call (888) 340-4807.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (888) 340-4807. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
SOURCE Bernstein Liebhard LLP